| Name | Title | Contact Details |
|---|---|---|
Kerry Flagg |
Chief Marketing and Communications Officer | Profile |
Evozyne is a data-driven evolution-based molecular engineering platform for building novel, application-specific proteins with advanced functionality.
Paradigm is a medical diagnostics company serving physicians and patients worldwide.
NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of those struggling with serious diseases. Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving development of transformational medicines that dramatically improve human health. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio`s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.
One Cell Systems is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nonlethal Technologies, Inc is a Homer City, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.